

Natco Pharma Limited

Regd. Off.: NATCO HOUSE, Road No. 2, Banjara Hills, Hyderabad - 500034. Telangana, INDIA. Tel: +91 40 23547532, Fax: +91 40 23548243 CIN: L24230TG1981PLC003201, www.natcopharma.co.in

February 17, 2018

Corporate Relationship Department

M/s. BSE Ltd Dalal Street, Fort Mumbai- 400 001 Manager – Listing

M/s. National Stock Exchange of India Ltd "Exchange Plaza", Bandra – Kurla Complex

Bandra (E) Mumbai -400 051

Scrip Code: **524816** Scrip Code: **NATCOPHARM**

Dear Sir

Please find enclose herewith the Press Release for your information.

Thanking you

Yours faithfully For NATCO Pharma Limited

MANarayana

M Adinarayana

Company Secretary &

Vice President (Legal & Corp Affairs)



Natco Pharma Limited

Regd. Off.: NATCO HOUSE, Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel: +91 40 23547532, Fax: +91 40 23548243
CIN: L24230TG1981PLC003201, www.natcopharma.co.in

Ref: PR/ 16 /2017-2018

Press Release

<u>USFDA COMPLETES INSPECTION OF NATCO's</u> MEKAGUDA API FACILITY WITH ZERO OBSERVATIONS

Hyderabad, India, February 17th, 2018

Natco Pharma Limited (NSE: NATCOPHARM; BSE: 524816) is pleased to announce successful completion of regulatory inspection from the United States Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredient (API) facility in Mekaguda Village, near Hyderabad, India, which was conducted during the period 12th February, 2018 to 16th February, 2018. The regulatory audit resulted in zero observations (no form 483 issued).

Forwarded for favour of publication For NATCO Pharma Limited

MANarayana

M Adinarayana
Company Secretary &
Vice President (Legal & Corp Affairs)